---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-041541"
form_type: "8-K"
ticker: "PRME"
cik: "0001894562"
company_name: "Prime Medicine, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:57:15.625450+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Prime Medicine inks $110M upfront BMS collaboration, refocuses pipeline, cash runway to H1 2026

## Summary
- Received $55M upfront + $55M equity investment ($5.00/share) from BMS for exclusive license to Prime Editing for ex vivo T-cell therapies.
- Up to >$3.5B in milestones ($1.4B development, >$2.1B commercialization) plus tiered royalties; BMS locked up shares until Sep 2027.
- Pipeline focus: Phase 1/2 CGD data expected in 2025; Wilson's Disease IND/CTA planned for H1 2026.
- X-linked CGD program added using PASSIGE technology; cystic fibrosis work continues with CFF funding.
- Cost savings plus BMS upfront extend cash runway into first half of 2026 (previously not guided beyond 2025).

## SEC filing metadata
- accession: 0001628280-24-041541
- form_type: 8-K
- ticker: PRME
- cik: 0001894562
- company_name: Prime Medicine, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1894562/000162828024041541/0001628280-24-041541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1894562/000162828024041541/prme-20240928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-041541
- JSON: https://secwatch.observer/filing/0001628280-24-041541.json
- Plain text: https://secwatch.observer/filing/0001628280-24-041541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.